Literature DB >> 28616864

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

Nicholas J Short1, Hagop Kantarjian2, Elias Jabbour2, Jorge E Cortes2, Deborah A Thomas2, Michael E Rytting2,3, Naval Daver2, Yesid Alvarado2, Marina Konopleva2, Partow Kebriaei4, William G Wierda2, Courtney D DiNardo2, Carol Bivins2, Deborah McCue5, Mary A Richie2, Farhad Ravandi2.   

Abstract

Entities:  

Keywords:  CD22; acute lymphoblastic leukaemia; immunotoxin; moxetumomab pasudotox; relapsed/refractory

Mesh：

Substances：

Year:  2017        PMID： 28616864      PMCID： PMC6511975          DOI： 10.1111/bjh.14806

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

2.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Authors:  Xing Du; Richard Beers; David J Fitzgerald; Ira Pastan
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

4.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

5.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Authors:  John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
Journal:  Blood       Date:  2008-11-06       Impact factor: 25.476

6.  Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Authors:  Masanori Onda; Richard Beers; Laiman Xiang; Byungkook Lee; John E Weldon; Robert J Kreitman; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 12.779
  6 in total
  3 in total

Review 1.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

2.  Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.

Authors:  Fabian Müller; Tyler Cunningham; Richard Beers; Tapan K Bera; Alan S Wayne; Ira Pastan
Journal:  Toxins (Basel)       Date:  2018-05-21       Impact factor: 4.546

Review 3.  Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Authors:  Veronica A Guerra; Elias J Jabbour; Farhad Ravandi; Hagop Kantarjian; Nicholas J Short
Journal:  Ther Adv Hematol       Date:  2019-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.